The treatment is recommended for people aged 12 to 65 who have moderate to severe and persistent allergic rhinitis and have been diagnosed through clinical history and a positive test of their house ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

New NHS treatment gives hope to thousands who suffer from common allergy - The first-of-its-kind tablet will offer relief ...

The following is a summary of “Anatomical and physiological contributions of nasal turbinate vessels and lymphatics to the ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Doctors shared their must-have sick season buys with The Post, revealing which medicines, supplements and tools you should ...

Yes, allergies can make you feel tired. Fatigue is a common allergy symptom, and it’s caused by factors like inflammation or ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.